Professor Szabo is a globally recognized expert in oxidative and nitrosative stress, gaseous transmitters, cell dysfunction, and inflammatory mechanisms. He pioneered the concept identifying the nuclear enzyme PARP's role in promoting cell necrosis, contributing to critical illnesses and cardiovascular diseases. In the last decade, Szabo focused on hydrogen sulfide, discovering its roles in shock, angiogenesis, cancer, and Down syndrome, leading to new therapeutic concepts. His recent work has also explored cyanide's biological roles in mammals. Trained as an M.D./Ph.D. in Budapest, Szabo worked as a postdoc with Nobel Laureate Sir John Vane in London. He then led multiple research groups across the USA in both academia and industry and now chairs the Pharmacology Section and the Department of Oncology, Microbiology and Immunology at the University of Fribourg (Switzerland). His work has led to clinical-stage drugs, significant transactions, pioneering of novel pathophysiological and pharmacological concepts and tools. He is recognized as one of the world's most cited pharmacologists with a H-index of 150. He has received numerous prestigious awards and serves on various editorial boards.